Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Isho, B.; Abe, K. T.; Zuo, M.; Jamal, A. J.; Rathod, B.; Wang, J. H.; Li, Z.; Chao, G.; Rojas, O. L.; Bang, Y. M.; Pu, A.; Christie-Holmes, N.; Gervais, C.; Ceccarelli, D.; Samavarchi-Tehrani, P.; Guvenc, F.; Budylowski, P.; Li, A.; Paterson, A.; Yue, F. Y.; Marin, L. M.; Caldwell, L.; Wrana, J. L.; Colwill, K.; Sicheri, F.; Mubareka, S.; Gray-Owen, S. D.; Drews, S. J.; Siqueira, W. L.; Barrios-Rodiles, M.; Ostrowski, M.; Rini, J. M.; Durocher, Y.; McGeer, A. J.; Gommerman, J. L.; Gingras, A. -C.

doi:10.1126/sciimmunol.abe5511

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., & Wang, J. H., et al. (2020). Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science Immunology, 5(52), eabe5511.
Added by: Dr. Enrique Feoli (11/10/2020, 09:46) Last edited by: Dr. Enrique Feoli (11/10/2020, 11:40)

Resource type: Journal Article
DOI: 10.1126/sciimmunol.abe5511
ID no. (ISBN etc.): 2470-9468
BibTeX citation key: Isho2020
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: Inmunidad de mucosas
Creators: Abe, Bang, Barrios-Rodiles, Budylowski, Caldwell, Ceccarelli, Chao, Christie-Holmes, Colwill, Drews, Durocher, Gervais, Gingras, Gommerman, Gray-Owen, Guvenc, Isho, Jamal, Li, Li, Marin, McGeer, Mubareka, Ostrowski, Paterson, Pu, Rathod, Rini, Rojas, Samavarchi-Tehrani, Sicheri, Siqueira, Wang, Wrana, Yue, Zuo
Collection: Science Immunology

Views: 2/246

Abstract

While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about the antibody response in saliva and its relationship to systemic antibody levels. Here, we profiled by enzyme-linked immunosorbent assays (ELISAs) IgG, IgA and IgM responses to the SARS-CoV-2 spike protein (full length trimer) and its receptor-binding domain (RBD) in serum and saliva of acute and convalescent patients with laboratory-diagnosed COVID-19 ranging from 3–115 days post-symptom onset (PSO), compared to negative controls. Anti-SARS-CoV-2 antibody responses were readily detected in serum and saliva, with peak IgG levels attained by 16–30 days PSO. Longitudinal analysis revealed that anti-SARS-CoV-2 IgA and IgM antibodies rapidly decayed, while IgG antibodies remained relatively stable up to 105 days PSO in both biofluids. Lastly, IgG, IgM and to a lesser extent IgA responses to spike and RBD in the serum positively correlated with matched saliva samples. This study confirms that serum and saliva IgG antibodies to SARS-CoV-2 are maintained in the majority of COVID-19 patients for at least 3 months PSO. IgG responses in saliva may serve as a surrogate measure of systemic immunity to SARS-CoV-2 based on their correlation with serum IgG responses.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli